3 completed, 1 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Terminated 1 |
Follow Hormone Refractory Prostate Cancer: new trials by email Literature Review of Hormone Refractory Prostate Cancer trials Research Report on Hormone Refractory Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel - Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer | Phase 3 | Terminated | Achieve Life Sciences | 14 | 2010-03-01 | 2016-10-12 |
| A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Best standard of care (BSoC) - Hormone Refractory Prostate Cancer, Bone Metastases | Phase 3 | Completed | Bayer | 921 | 2008-06-12 | 2026-02-23 |
| Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer Denosumab, Placebo - Hormone Refractory Prostate Cancer | Phase 3 | Completed | Amgen | 1435 | 2006-01-24 | 2018-10-17 |
| Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen Satraplatin, Prednisone - Prostate Cancer, Hormone Refractory Prostate Cancer | Phase 3 | Completed | Agennix | 2003-09-01 | 2012-08-07 |
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Prednisone (2) · Denosumab (1) · Docetaxel (1) · OGX-011 (1) · Sodium Chloride (1) · cabazitaxel (1) · radium Ra 223 dichloride (1) · satraplatin (1)
Achieve Life Sciences (1) · Agennix (1) · Amgen (1) · Bayer (1)
France (3) · Spain (3) · United Kingdom (3) · United States (3) · Belgium (2) · Canada (2) · Germany (2) · Israel (2) · Italy (2) · Netherlands (2) · Poland (2) · Argentina (1) · Australia (1) · Brazil (1) · Croatia (1)
Christopher Parker, MD (1) · Karim Fizazi, M.D., Ph.D. (1) · Sebastien J Hotte, M.D. (1) · Tomasz M Beer, M.D. (1)
PMID 22093187, PMID 23863050, PMID 23977665, PMID 24052017, PMID 24610703, PMID 24775727, PMID 24836273, PMID 24857093, PMID 25439694, PMID 25832684, PMID 25840395, PMID 27930924